9 research outputs found
Partial Splenic Embolization: Successful treatment of hypersplenism, secondary to biliary cirrhosis and portal hypertension in cystic fibrosis
AbstractPartial Splenic Embolization (PSE) is a non-surgical treatment for hypersplenism. It has been reported only in a limited number of patients with Cystic Fibrosis (CF). We report a case of a female cystic fibrosis patient who developed hypersplenism at the age of 14 and underwent PSE. Long term results over a period of 14 years after the procedure are presented
Adiponectin and body composition in cystic fibrosis
AbstractThe aim of the study was to evaluate adiponectin (AD) serum concentrations in 43 stable CF patients and 27 healthy subjects and to correlate them with their nutritional status. Body Composition (Bioelectrical Impedance), visceral/subcutaneous adipose tissue (VAT-SAT) in CF patients (CT-scan at L4), insulin resistance (HOMA-IR) and AD serum concentrations (ELISA) were studied. CF patients and controls had comparable weight, height, %BF, %FFM, fasting glucose, insulin and insulin resistance. CF patients had significantly lower BMI-SDS. CF males had higher %FFM and total FFM and lower %BF and total BF than females (p<0.001). Serum AD was higher in CF patients than controls (11.53±5.37 vs. 9.07±4.41 μg/ml) and comparable between females and males. AD was lowest among young malnourished patients (8.06±1.85 μg/ml) and highest among young patients with normal nutrition (14.56±7.69 μg/ml). Patients with biliary cirrhosis had higher levels than patients with normal liver (10.52±5.49 vs. 14.04±4.52 μg/ml, p<0.05). AD correlated with %BF, %FFM, FFM (kg) (p<0.05).VAT was significantly increased in malnourished patients. AD was not affected by VAT. Conclusions: Adiponectin is higher in CF patients than healthy individuals. It is decreased in malnourished young patients and increased in patients with normal nutrition and in patients with liver disease. This may be attributed to the reduced BF and to the energy deficit inherent to the disease
Successful pregnancy and delivery in a young woman with cystic fibrosis and gestational diabetes
Fecal elastase-1 cut-off levels in the assessment of exocrine pancreatic function in cystic fibrosis
Partial Splenic Embolization: Successful treatment of hypersplenism, secondary to biliary cirrhosis and portal hypertension in cystic fibrosis
Ghrelin and leptin levels in young adults with cystic fibrosis: Relationship with body fat
Results from the Pediatric European Register for Treatment of Helicobacter pylori (PERTH)
Background and Aim: Data on the eradication treatment for childhood
Helicobacter pylori are scanty. A register was established on the
European Society for Pediatric Gastroenterology Hepatology and Nutrition
(ESPGHAN) website to collect data on treatment performed by European
pediatricians to ascertain what is practiced in the field.
Subjects: From January 2001 to December 2002, information on 597
children were entered by 23 European Centers, but only data of 518
treated children were completed and analyzed (86.7%, 262 male subjects,
median age 9 years, range 1-14). According to their nationality, 226
children were from Southern Europe, 132 from Eastern Europe, 68 from
Western Europe, and 4 from northern Europe, 68 from North Africa, and 20
from Asia. At endoscopy, 454 children had gastritis and 64 had ulcer
(12.3%). Antibiotic sensitivity, tested in 361 cases, revealed 18%
clarithromycin-resistant and 19% metronidazole-resistant H. pylori
strains.
Results: Treatment was performed for 1 week in 388 and for 2 weeks in
130 children. Antibiotics were associated with proton pump inhibitors
(PPI) in 345 and with bismuth in 121 children. Triple therapy was given
to 485 children, dual therapy to 26, quadruple to 7. Follow-up data, by
C-13-Urea-Breath Test or histology or both, were available for 480
children. Overall eradication rate was 65.6%, significantly higher in
children with ulcer (79.7%) than without (63.9%, p = .001). When given
as first treatment, bismuth-containing triple therapies were more
efficacious than PPI-containing ones (77% versus 64%, p = .02, OR
1.88, 95% CI 1.1-3.3). Twenty-seven different treatment regimens were
used, but only six were administered to at least 18 children (range
18-157). There was no difference between treatments given for 1 or 2
weeks, or given as first or second therapies.
Conclusion: European pediatricians entering data in the register used 27
different regimens. Bismuth-containing therapies resulted in higher
eradication rate. Omeprazole-containing triple therapies were the most
used although their efficacy was low. Therapies recommended for adults
do not appear to be suitable for children